University Hospital Complex A Coruña

 

Web Site

www.inibic.org

Research Lines

a) Research lines and their main contributions: The group has focused on the study of antimicrobial resistance mechanisms, in the development of technology that quickly and accurately to diagnose an infection by a microorganism and its antimicrobial susceptibility, and in the understanding the persistence and the virulence of the nosocomial pathogen A. baumannii.

In particular, i) it has also patented two technologies to measure through DNA fragmentation sensitivity or resistance of specific pathogens to antimicrobials; ii) The group has validated molecules capable of inhibiting enzymes involved in carbapenem antibiotic resistance in A. baumannii (Bou G. J Am Chem Soc 2010); iii) Characterization for the first time the biofilm of A. baumannii (Cabral MP J Proteome Res 2011); iv)They have demonstrated the importance of outer membrane vesicles (OMVs) in the dissemination of carbapenem resistance

genes in A. baumannii (Rumbo C.AAC 2011) as a new mechanism of spreading of antimicrobial resistance genes in this specie; v) They have also elucidated the biochemical mechanism of the class D-beta-lactamases of A. baumannii (PNAS.2007. 104 (13): 5354-9); and vi) Characterization for the first time of the proteome of A. baumannii (Soares NC. Proteome Sci. 2009.28;7:37); vii- The identification of the mechanism and proteins involved in stress response andpersistence of A. baumannii (Soares NC. J Proteome Res 2010.9: 1951-64; Aranda J. J. Bacteriology.2011.193: 3740-7) and finally viii- Molecular basis for colistin resistance in A. baumannii (Beceiro A. AAC. 2011.55: 3370-9).

Finally, they have validated a kit which is based on the determination of DNA fragmentation to measure sensitivity or resistance to antimicrobials (BMC Microbiol. 2009. 13; 9:69; J Clin Microbiol. 2009 Aug;47(8):2593-5; BMC Microbiol. 2011.11: 191); J Clin Microbiol. 2012 Nov;50(11):3609-13.

b) International manuscripts last five years: 64, 19 in D1 and 42 in Q1; in collaboration with other groups from REIPI: 22. IF accumulated: 274.95.

c) Competitive funds for projects: 19 grants as IP, 1,492,385.30 €; International: 1, National: 6, and Regional: 7; private institutions 5.

d) Consensus Documents and Guidelines: one, national;

e) Patents: i) Process for determining DNA fragmentation in microorganisms: International application NQ. Application No.07823042.2-2402; PCT/ES2007/000637.

ii) Method for determining rapid sensitivity or resistance to antibiotics acting on bacteria cell wall. No. P6190ES00;

iii) Procedure for the clinical diagnosis of an infectious disease based on the use of quantitative PCR, labeled oligonucleotides of 8-9 nucleotides in length and Atlantic Cod UNG (Gadus morhua).Nº P201231456.

f) This group is also involved in the Spanish platform of clinical trials (CAIBER) (www.caiber.net).

Group Coordinator

Dr. Germán Bou Arévalo